Article: 'Proventil Repetabs,' Schering-Plough's new asthma product, is approved for marketing in United States.

'PROVENTIL REPETABS,' SCHERING-PLOUGH'S NEW ASTHMA PRODUCT,

IS APPROVED FOR MARKETING IN UNITED STATESPRODUCT,

MADISON, N.J., July 14 /PRNewswire/ -- 'Proventil Repetabs,' Schering-Plough Corporation's (NYSE: SGP) new, long-acting asthma medication, has been approved for marketing in the United States by the U.S. Food and Drug Administration and will be introduced in August.

A prescription product from Schering Laboratories, 'Proventil Repetabs' is the first and only beta agonist bronchodilator to be marketed in the United States for twice-a-day use. The new tablets are indicated for relief of symptoms associated with asthma, ...

Related newspaper, magazine, and journal articles:

 
 
Newsweek Harper's Magazine The Washington Post Chicago Tribune Crain's Chicago Business PRNewswire Pediatric News The Nation Advertising Age The Economist (US) A FREE trial gives you access to over 80 million articles! Access over 6,500 publications with a FREE trial!